Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

The antifibrotic effect of empagliflozin: Insights from the EMPIRE trial programme

Sodium-glucose co-transporter 2 (SGLT2) inhibitors are foundational in treating patients with heart failure (HF), type 2 diabetes (T2D), and chronic kidney disease (CKD). One proposed mechanism behind the clinical effect is attenuation of fibrotic pathways. However, clinical data to support this mechanism are lac...

J. Jensen, C. Andersen, M. Omar et al. · 0 citations
Open access Oct 2026

Dapagliflozin in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: the DAPAH randomized controlled trial

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce mortality in left heart failure. In pre-capillary pulmonary hypertension (PH), preclinical data suggest SGLT2i may improve right ventricular (RV) function through metabolic modulation, reduced perivascular inflammation, and inhibition of vascular remodelin...

M. Ersboll, J. Kjaergaard, F. Gustafsson et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.